By
Drug Target Review2024-06-04T12:30:07
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-13T10:14:00Z
2023-05-30T13:51:56
Sponsored by BPS Bioscience
2026-06-24T13:00:00 2026-06-24T14:00:00
Sponsored by HUB Organoids
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud